Kringle Pharma
Kringle Pharma is a late clinical-stage biopharmaceutical company dedicated to developing regenerative medicines based on HGF (Hepatocyte Growth Factor) protein. Their mission is to bring breakthrough HGF protein-based therapies to patients suffering from intractable and mainly rare diseases. The company leverages its expertise in manufacturing pharmaceutical-grade HGF protein to advance therapeutic drug development for conditions with significant unmet medical needs.
Kringle Pharma
What We Do
A regenerative drug candidate currently in clinical trials for several intractable, mainly rare, diseases. The product is based on HGF, an endogenous protein with protective, regenerative, and repairing functions in tissues and organs.
Key People
Kazunori Maebashi
Director, Pharmaceutical Department
Matthew Vogelhuber
Business Development, the US representative
News & Updates
Kringle Pharma's recombinant human HGF, KP-100IT, received Orphan Drug Designation from the U.S. FDA for the treatment of acute spinal cord injury.
An analyst report on Kringle Pharma was released by Shared Research Inc.
Kringle Pharma released its financial results for the nine months ended June 30, 2025, under Japanese GAAP (Non-consolidated).
An analyst report on Kringle Pharma was released by Shared Research Inc.
The U.S. FDA granted Orphan Drug Designation to Kringle Pharma's recombinant human HGF, KP-100IT, for the treatment of acute spinal cord injury.